Effect of zinc supplementation on growth Hormone Insulin growth factor axis in short Egyptian children with zinc deficiency by Rasha T Hamza et al.
Hamza et al. Italian Journal of Pediatrics 2012, 38:21
ITALIAN JOURNAL 
OF PEDIATRICS
http://www.ijponline.net/content/38/1/21RESEARCH Open AccessEffect of zinc supplementation on growth
Hormone Insulin growth factor axis in short
Egyptian children with zinc deficiency
Rasha T Hamza1*†, Amira I Hamed2† and Mahmoud T Sallam3†Abstract
Background: The relationship between zinc (Zn) and growth hormone-insulin growth factor (GH-IGF) system and
how Zn therapy stimulates growth in children has not been clearly defined in humans. Thus, we aimed to assess
GH-IGF axis in short children with Zn deficiency and to investigate the effect of Zn supplementation on these
parameters.
Methods: Fifty pre-pubertal Egyptian children with short stature and Zn deficiency were compared to 50 age-, sex-,
and pubertal stage- matched controls. All subjects were subjected to history, auxological assessment and
measurement of serum Zn, IGF-1, insulin growth factor binding protein-3 (IGFBP-3); and basal and stimulated GH
before and 3 months after Zn supplementation (50 mg/day).
Results: After 3 months of Zn supplementation in Zn-deficient patients, there were significant increases in height
standard deviation score (SDS, P = 0.033), serum Zn (P< 0.001), IGF-1 (P< 0.01), IGF-1 standard deviation score (SDS,
P< 0.01) and IGFBP-3 (P = 0.042). Zn rose in all patients but reached normal ranges in 64 %, IGF-1 levels rose in
60 % but reached normal ranges in 40 % and IGFBP-3 levels rose in 40 % but reached reference ranges in 22 %.
Growth velocity (GV) SDS did not differ between cases and controls (p = 0.15) but was higher in GH-deficient
patients than non-deficient ones, both having Zn deficiency (p = 0.03).
Conclusion: Serum IGF-1 and IGFBP-3 levels were low in short children with Zn deficiency, and increased after Zn
supplementation for 3 months but their levels were still lower than the normal reference ranges in most children;
therefore, Zn supplementation may be necessary for longer periods.
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Although Zn deficiency is a common nutritional problem
around the world, especially in children in developing
countries where diets have less Zn available, it is difficult to
identify this problem. Zn is important for the metabolic
activity of more than two hundred enzymes. It is essential
for cell replication, and deoxyribonucleic acid (DNA) and
protein synthesis. Zn deficiency is reported to be associated
with impairment of growth, testicular functions, appetite,* Correspondence: rashatarif_2000@hotmail.com
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reproduction in any medium, provided the orand sense of taste, delay in wound healing, immune
resistance and memory. Zn deficiency interferes with the
metabolism of thyroid hormones, androgens and growth
hormone (GH). It is not known what mechanism is respon-
sible for growth retardation in Zn deficiency and how Zn
therapy stimulates growth in children [1].
The principal regulator of growth in the body is the
GH-IGF system [2]. It appears that Zn supplementation
has positive effects on growth and IGF-1 levels in various
groups of Zn-deficient children. However, the exact mech-
anism of Zn deficiency and the mechanism by which Zn
supplementation affects GH secretion and IGF-1 levels is
not well delineated. Furthermore, the effect of Zn supple-
mentation on the GH-IGF axis in non Zn-deficient shortLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tive effects of Zn supplementation on growth in various
groups of Zn-deficient children [3-5]. However, in some
studies, this effect was not observed [6,7].
With this background, we were stimulated to assess
GH-IGF axis in short children with Zn deficiency and to




This prospective case control study was conducted on 50
pre-pubertal Egyptian children with short stature and Zn
deficiency [27 males (54 %), 23 females (46 %)] whose ages
ranged between 3.2 and 10.9 years (mean age:
6.5 ± 3.05 years). All patients were shorter than expected
for their chronological age and sex (height SDS<−2) [8].
Patients were recruited from Nile Hospital, Egyptian
Health Insurance (n= 32) and the Pediatrics Outpatient
Clinic, Children's hospital, Faculty of Medicine, Ain
Shams University, Cairo, Egypt (n= 18) during the period
from the beginning of April 2010 to the end of August
2011. Cases were compared to 50 healthy age-, sex- and
pubertal stage- matched children serving as controls who
had normal serum Zn levels. They were 28 males (56 %)
and 22 females (44 %) whose ages ranged between 3.5 and
10.8 years (mean age: 6.7 ± 2.05 years). They were
recruited from the Pediatrics Outpatient clinic, Children`s
hospital, Faculty of Medicine, Ain shams University, Cairo,
Egypt.
Children with chronic systemic diseases, bone dysplasias,
dysmorphic syndromes, chronic malabsorption, other
nutritional deficiencies, short stature with normal serum
Zn levels (>109 μg/dl), other endocrine problems e.g
hypothyroidism and history of long-term medications that
might influence the GH-IGF axis were excluded from the
study. In addition, all patients were not on GH therapy
during the time of the study.
An informed written consent of participation in the study
was signed by the parents or legal guardians of the studied
subjects. This study was approved by the Bioethical
Research Committee, Faculty of Medicine, Ain Shams
University hospitals, Cairo, Egypt.
Study measurements
All studied children were subjected to:
 Medical history and clinical assessment: laying stress
on therapeutic history, systemic examination and
dysmorphic features.
 Auxological parameters: Height was measured to
the nearest 1.0 mm with a Harpenden wall mounted
stadiometer and weight to the nearest 0.1 kg on
electronic scales together with calculation of heightfor age, weight for height and height velocity
Standard Deviation Scores (SDSs) [8]. Body Mass
Index (BMI) was calculated using the formula
weight (in kg)/height2 (in meters) together with
calculation of BMI SDS calculated from the age- and
sex-specific reference values [9].
 Tanner pubertal staging: for assessment of pubertal
status according to the standards of Tanner and
Whitehouse (1976) [10]
 Laboratory assays: All blood samples were taken in
the morning after an overnight fast for
measurement of the following:
– Serum Zn which was measured by a
spectrophotometric method after deproteinization
of samples. The normal reference range ranged
from109-167 ng/dl while serum Zn values below
109 μg/dl indicated Zn deficiency [11].
– Serum IGF-1 and IGFBP-3 that were measured
using a solid phase, enzyme labeled
chemiluminescent immunometric assay. Values
were expressed as absolute values (ng/ml) and
were also expressed as SDS for age and sex
according to normal reference ranges of
Elmlinger et al., 2004 [12]
– Basal and stimulated serum GH levels after
insulin induced hypoglycemia, in which baseline
GH and glucose samples were withdrawn and
regular insulin was administered in a dose of 0.1
unit/kg intravenously and samples for
measurement of GH and glucose were withdrawn
at 30, 60, 90 and 120 minutes. Blood glucose
must decrease by 50 % of the initial value or to
<40 mg%. In addition, GH provocation test by
clonidine was done to confirm the diagnosis of
growth hormone deficiency (GHD) in which a
baseline GH sample was withdrawn and clonidine
was administered in a dose of 5 μg/kg orally and
samples for measurement of GH were withdrawn
at 30, 60, 90 and 120 minutes. Normally, GH
should rise to a peak of ≥10 ng/ml at any of the
post-stimulatory samples. Patients with peak GH
levels <10 ng/ml by the 2 stimulatory tests were
considered GH-deficient [13]. Serum GH
concentrations were measured using commercial
reagents (Pharmacia Diagnostics, Uppsala,
Sweden) by a solid-phase, enzyme-labeled
chemiluminiscent immunometric assay (by the
Immulite, 2000 Analyzer, Siemens).
 Bone age (BA) was done by performing plain X ray
left hand and wrist together with calculation of bone
age SDS according to the standards of Greulich and
Pyle [14].
Table 1 Descriptive clinical, laboratory and radiological
data of studied cases (n = 50)
Mean± SD Range
Age (years) 6.5 ± 3.05 3.20-10.90
Height SDS -3.12 ± 0.2 -2.15- -4.21
-GV after Zn (cm/3 months) 0.55 ± 0.1 0.1-2.23
-GV SDS after Zn +1.01 ± 0.2 -0.5 - +2.11
- Weight SDS -1.88 ± 0.62 -2.01- +0.55
- BMI SDS -1.77 ± 0.41 -2.10- -0.78
- Serum Zn (μg/dl) 56.76 ± 7.90 37.52-93.11
-Peak GH after insulin
stimulation (ng/ml)
10.65 ± 2.01 7.61-13.20
-Peak GH after clonidine
stimulation (ng/ml)
11.14 ± 1.41 6.92-14.11
- IGF-1 (ng/ml) 96.72 ± 11.5 36.52-115.69
-IGF-1 SDS -2.46 ± 0.11 -3.22- +0.55
- IGFBP-3 (ng/ml) 2436.12 ± 392 1195.45-3898.15
-BA (years) 3.7 ± 1.05 1.81-9.25
-BA SDS -1.75 ± 1.14 -2.44 - +0.22
Results are expressed as mean± SD and range, Zn: zinc, SDS: Standard
deviation score, GV: Growth velocity, BMI: Body mass index, GH: Growth
hormone, IGF-1: Insulin like growth factor-1, IGFBP-3: Insulin like growth factor
binding protein-3, BA: bone age.
Table 2 Comparison of clinical, laboratory and
radiological data among cases and controls
Cases Controls t p
(N= 50) (N= 50)
Age (years) 6.5 ± 3.05 6.7 ± 2.05 1.2 0.11
(3.2 -10.9) (3.5-10.8)
Sex , n(%)
Males 27(54 %) 28 (56 %) 1.11 0.23
Females 23(46 %) 22(44 %)
Height SDS -3.12 ± 0.2 +1.04 ± 0.5 19.88 <0.001***
(-2.15- -4.21) (+0.99 - +1.65)
GV after Zn
(cm/3 months)
0.55 ± 0.1 0.61 ± 0.1 0.82 0.11
(0.1-2.23) (0.2-3.13)
GV SDS +1.01 ± 0.2 +1.21 ± 0.1 1.3 0.15
(-0.5 - +2.11) (-0.3 - +2.31)
Weight SDS -1.88 ± 0.62 -1.02 ± 0.71 1.7 0.2
(-2.01 - +0.55) (-1.20 - +1.45)
BMI (kg/m2) 16.41 ± 1.56 17.51 ± 0.52 1.0 0.3
(14.33-20.12) (14.33-20.12)
BMI SDS -1.77 ± 0.41 -1.02 ± 0.31 1.99 0.082
(-2.10- -0.78) (-1.30 - +0.23)
Serum Zn (μg/dl) 56.76 ± 7.90 136.70 ± 8.10 22.5 <0.001***
(37.52-93.11) (123.17-149.50)
Peak GH after insulin
stimulation (ng/ml)





11.14 ± 1.41 15.24 ± 2.11 6.81 0.041*
(6.92-14.11) (11.12-19.21)
IGF-1 (ng/ml) 96.72 ± 11.5 286.62 ± 12.5 12.86 <0.001***
(36.52-115.69) (198.72-325.19)
IGF-1 SDS -2.46 ± 0.11 +1.46 ± 0.21 17.66 <0.001***
(-3.22- +0.55) (+0.89 - +1.85)





-BA (years) 3.7 ± 1.05 6.8 ± 1.6 6.11 0.020*
(1.81-9.25) (3.31-11.25)
-BA SDS -1.75 ± 1.14 +0.85 ± 1.20 13.24 <0.001***
(-2.44 - +0.22) (+1.04 - +0.22)
Results are expressed as mean± SD and range frequency and percentage,
*p< 0.05, **p< 0.01, ***p< 0.001, GHD: growth hormone deficiency, SDS:
Standard deviation score, GV: growth velocity, Zn: zinc, BMI: Body mass index,
Zn: zinc, GH: Growth hormone, IGF-1: Insulin like growth factor-1, IGFBP-3:
Insulin like growth factor binding protein-3, BA: bone age.
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to all subjects for 3 months after which auxological
assessment was repeated and serum samples were
withdrawn to repeat all laboratory assays. In
addition, growth velocity (GV) after 3 months of Zn
therapy was calculated. GV is the variable that
describes the patient's one year or 6 months or
3 months height velocity. GV SDS was calculated
according to the norms of Tanner etal, 1966 [8].
Statistical analysis
The results were analyzed using the Statistical Package for
the Social Science (SPSS) version number 10, Echosoft
corp; USA, 2005. Description of quantitative variables was
in the form of mean± standard deviation and range while
that of qualitative variables was in the form of frequency
and percentage. Student’s t-test of 2 independent samples
was used to compare 2 quantitative variables while
Wilcoxon Signed Rank test was used to compare 2
dependent groups before and after Zn supplementation.
Spearman correlation coefficient test (r-test) was used to
rank different variables against each other either directly or
indirectly. A p-value of <0.05 was considered significant.
Results
Characteristics of studied cases
Descriptive clinical, laboratory and radiological data of
studied cases are presented in Table 1. Of the 50 studied
cases, serum IGF-1 levels were below the normal age-matched reference ranges in 47(94 %) while serum
IGFBP-3 concentrations were below the normal age-
matched reference ranges in all children (100 %). In
addition, GHD was diagnosed in 25 cases (50 %), that is, a
peak GH of< 10 ng/ml by 2 GH provocation tests. The
Table 3 Comparison of clinical, laboratory and
radiological data of studied cases with and without GHD
With GHD Without GHD t p
(N= 25) (N= 25)
Height SDS −3.52 ± 0.3 −2.56 ± 0.1 6.11 0.043*
(−2.85- -4.21) (−2.15- -2.91)
GV (cm/3 months) 1.21 ± 0.2 0.85 ± 0.1 5.99 0.041*
(0.7-2.23) (0.1-1.83)
GV SDS +1.56 ± 0.5 +0.91 ± 0.2 7.12 0.030*
(+0.72 - +2.11) (-0.5 - +1.86)
Weight SDS -1.68 ± 0.12 -1.58 ± 0.52 1.9 0.5
(-1.99 - +0.55) (-2.01- +0.25)
BMI (kg/m2) 16.91 ± 0.25 17.31 ± 0.46 1.8 0.3
(15.56-18.12) (14.53-17.92)
BMI SDS -1.81 ± 0.10 -1.72 ± 0.32 2.1 0.5
(-1.9- -0.78) (-2.10- -0.82)
Serum Zn (μg/dl) 45.71 ± 2.9 76.16 ± 5.9 18.12 <0.001***
(37.52-61.55) (39.12 - 93.11)
Peak GH after insulin
stimulation(ng/ml)





7.14 ± 0.12 12.54 ± 1.21 10.16 0.01*
(6.92-8.53) (10.88-14.11)
IGF-1 (ng/ml) 46.78 ± 6.5 100.12 ± 12.5 16.22 <0.001***
(36.52-59.11) (72.55-115.69)
IGF-1 SDS -2.72 ± 0.10 +0.38 ± 0.21 19.01 <0.001***
(-3.22- -2.11) (-1.20- +0.55)





-BA (years) 2.8 ± 1.0 5.7 ± 1.26 8.15 0.03*
(1.81-5.9) (4.-9.25)
-BA SDS -1.7 ± 0.12 -0.7 ± 0.14 11.22 0.01*
(-2.44 - +0.01) (-1.14 - +0.22)
Results are expressed as mean± SD and range, *p< 0.05, **p< 0.01,
***p< 0.001, GHD: growth hormone deficiency, SDS: Standard deviation score,
GV: growth velocity, BMI: Body mass index, Zn: zinc, GH: Growth hormone,
IGF-1: Insulin like growth factor-1, IGFBP-3: Insulin like growth factor binding
protein-3, BA: bone age.
Table 4 Comparison of clinical, laboratory and
radiological data of studied cases (n =50) before and
3 months after Zn supplementation
Before Zn After Zn z p
Height SDS −3.12 ± 0.2 −1.87 ± 0.1 6.76 0.033*
(−2.15- -4.21) (−2.0- -3.11)
Weight SDS -1.88 ± 0.62 -1.72 ± 0.51 1.83 0.21
(-2.01- +0.55) (-2.05- + 0.66)
BMI (kg/m2) 16.41 ± 0.56 16.58 ± 0.22 1.59 0.11
(14.33-18.12) (14.91-18.42)
BMI SDS -1.77 ± 0.41 -1.58 ± 0.32 1.80 0.26
(-2.10- -0.78) (-0.91- -1.95)










11.14 ± 1.41 12.99 ± 1.22 1.15 0.090
(6.92-14.11) (8.90-14.82)
IGF-1 (ng/ml) 96.72 ± 11.5 177.50 ± 9.06 7.12 <0.010**
(36.52-115.69) (42.65-213.66)
IGF-1 SDS -2.46 ± 0.11 -0.91 ± 0.43 9.16 <0.010**
(-3.22- +0.55) (-2.95 - +1.10)
IGFBP-3 (ng/ml) 2436.12 ± 392 2856.30 ± 411 5.90 0.042*
(1195.45-3898.15) (1341.10-3912.51)
-BA (years) 3.7 ± 1.05 4.12 ± 1.32 1.25 0.081
(1.81-9.25) (2.13-9.81)
-BA SDS -1.7 ± 1.14 -1.5 ± 1.21 0.13 0.35
(-2.44 - +0.22) (-2.10- + 0.65)
Results are expressed as mean± SD and range, *p< 0.05, **p< 0.01,
***p< 0.001, Zn: zinc, SDS: Standard deviation score, BMI: Body mass index,
GH: Growth hormone, IGF-1: Insulin like growth factor-1, IGFBP-3: Insulin like
growth factor binding protein-3, BA: bone age.
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mentation was 0.55± 0.1 (range:0.1-2.23) with a GV SDS
of +1.01 ± 0.2 (range: -0.5 - +2.11, Table 1).Cases versus controls
Height SDS (p< 0.001), serum Zn (p< 0.001), peak GH
after insulin (P=0.04) and clonidine stimulation (P=0.041),
IGF-1 (P< 0.001), IGF-1 SDS (p< 0.001), IGFBP-3
(P< 0.001), BA (p=0.02) and BA SDS (p< 0.001) were sig-
nificantly lower among cases than controls. On the otherhand, other clinical parameters and; GV and GV SDS did
not differ between both groups (p> 0.05, Table 2).
Cases with GHD versus cases without GHD
Height SDS (p=0.043), serum Zn (p< 0.001), peak GH
after insulin (P=0.021) and clonidine stimulation (P=0.01),
IGF-1 (P< 0.001), IGF-1 SDS (p< 0.001), IGFBP-3
(P=0.01), BA (p=0.03) and BA SDS (p=0.01) were signifi-
cantly lower among cases with GHD when compared to
those without GHD. On the other hand, cases with GHD
had significantly higher GV (p=0.041) and GV SDS
(p=0.03) when compared to those without GHD (Table 3).
Characteristics of cases before and 3 months after Zn
supplementation
On comparing clinical, laboratory and radiological para-
meters among all studied patients before and 3 months
Figure 1 Correlations between serum zinc and each of serum IGF-1 (Figure 1A) and serum IGFBP-3 (Figure 1B).
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in height SDS (P= 0.033), serum Zn (P< 0.001), IGF-1
(P< 0.01), IGF-1 SDS (p< 0.01) and IGFBP-3 (P= 0.042)
while other clinical and laboratory parameters did not dif-
fer 3 months after Zn supplementation (P> 0.05, Table 4).
Serum Zn levels rose in all patients but reached normal
reference ranges in 32 cases (64 %), serum IGF-1 levels rose
in 30 cases (60 %) but reached normal reference ranges in
20 cases (40 %) and serum IGFBP-3 levels rose in 20 cases
(40 %) but reached normal reference ranges in 11 cases
(22 %). There were no adverse effects other than mild nau-
sea in some patients during the Zn supplementation
period.
Relation between serum Zn and each of laboratory and
radiological parameters among studied cases
There were significant positive correlations between serum
Zn level and each of serum IGF-1 (r= 0.938, p< 0.0001,
Figure 1A), IGF-1 SDS (r= 0.81, p< 0.001) and IGFBP-3
levels (p=0.910, p< 0.0001, Figure 1B) before Zn supple-
mentation. On the other hand, serum Zn did not correlate
significantly with peak stimulated GH after insulin induced
hypoglycemia (r =0.17, p=0.31) and clonidine stimulation
(r= 0.13, p=0.23), BA (r =0.15, p= 0.13) and BA SDS
(r= 0.11, p= 0.22).
Discussion
Zn deficiency in humans is widespread throughout the
world especially in developing countries. In Egypt,
growth retardation and short stature due to Zn defi-
ciency are commonly observed. This could be explained
by the fact that intakes of animal products and animal
protein are very low due to low socio-economic status ofthe population. In addition, Zn intake is not only low,
but its bioavailability is poor because of the high phytate,
fiber and tea content of the diet among Egyptian popula-
tion [15]. Zn deficiency during the period of growth
results in growth failure and lack of gonadal develop-
ment, especially in males. Other effects of Zn deficiency
include skin changes, poor appetite, mental lethargy,
delayed wound healing, neurosensory disorders and cell-
mediated immune disorders [1].
Cesur et al, 2009 [16] found that serum IGF-1 and
IGFBP-3 were below normal reference ranges in 96.6 %
and 100 % of their short children with Zn deficiency
which is close to our findings (94 % and 100 % respect-
ively). It is not known what mechanism is responsible
for growth retardation in Zn deficiency and how Zn
therapy stimulates growth in children [1]. Moreover, the
exact mechanism of the effects of Zn deficiency and Zn
supplementation on GH secretion, serum IGF-1 levels,
and growth is not well delineated [3].
The current study revealed significant increases in
height SDS, GV and its SDS; serum Zn, IGF-1 and
IGFBP-3 after 3 months of Zn therapy with no
difference in GV between Zn deficient cases and non
Zn-deficient controls. Our findings were supported by
other studies [3-5,17,18] who reported that Zn supple-
mentation was effective for inducing growth in short
children with Zn deficiency in a rate similar to that in
healthy children. However, in some studies, this effect
was not observed [6,7]. Ninh et al [19] showed that Zn
supplementation increased both weight and height after
five months compared with placebo treatment but this
was not the case in our study concerning the weight.
According to these findings, some studies [19-21]
Hamza et al. Italian Journal of Pediatrics 2012, 38:21 Page 6 of 7
http://www.ijponline.net/content/38/1/21suggested that the growth- stimulating effect of Zn
might be mediated through changes in circulating IGF-1
levels.
On the other hand, an experimental study in rats [22]
showed that restoration of normal circulating levels of
IGF-1 and IGFBP-3 by recombinant IGF-1 infusion failed
to reverse the growth retardation induced by Zn defi-
ciency. They suggested that growth retardation related to
Zn deficiency is caused not only by low serum IGF-1 con-
centrations, but also by inhibition of the anabolic actions
of IGF-1. Moreover, it has been shown that Zn deficiency
also leads to alterations in the distribution of serum
IGFBPs, in addition to lower circulating IGF-1 concentra-
tions [21]. This theory was further supported by the strong
positive correlations between serum Zn and each of IGF-1,
IGF-1 SDS and IGFBP-3 levels reported in our study. In
addition, other studies [20,21] suggested a state of GH re-
sistance rather than GHD in case of Zn deficiency.
In addition, Imamoglu et al [23] reported that Zn
supplementation increased IGF-1 and IGFBP-3 in non-
Zn-deficient children with idiopathic short stature. They
suggested several explanations for this observation. First,
Zn supplementation may have increased the sensitivity to
endogenous GH. Secondly, Zn supplementation may have
increased the physiological GH secretion (i.e. sleep asso-
ciated) without altering GH response to pharmacological
stimulation. Alternatively, Zn may have non-GH mediated
(direct) effects on the synthesis of IGF-1 and IGFBP-3.
Support for the first hypothesis comes from animal studies
in which ionic Zn exerted a dose dependent stimulation of
hGH specific binding to isolated rat adipocytes [24]. Fur-
thermore, Zn ion was found to induce dimerization of
human GH [25] and to enhance the bioactivity of hGH
[26]. In vivo studies demonstrated that Zn deficiency
markedly decreased expression of IGF-1 and GH receptor
genes in the liver of growing rats [27]. Support for the
third hypothesis comes from the observation that Zn defi-
ciency causes a post-receptor defect in GH action, and a
decrease in IGF-1 gene expression which is reversed by
Zn supplementation but not by GH administration [28].
This hypothesis was further supported in our study by the
finding of higher GV after 3 months of Zn supplementa-
tion in GH-deficient than non GH-deficient, both having
Zn deficiency.
On the other hand, some reports found increased GH
response to pharmacological stimulation after Zn sup-
plementation in Zn-deficient children [5,21,29,30] which
was not the case in our study. Siklar et al [30] suggested
that during GH treatment in GH deficient children, Zn
status should be evaluated, as severe Zn deficiency could
decrease the response to GH treatment which is
improved with correction of Zn deficiency [30].
In the current study, after 3 months of Zn supplementa-
tion, serum Zn levels rose in all patients but reachednormal reference ranges in 32 cases (64 %), serum IGF-1
levels rose in 30 cases (60 %) but reached normal reference
ranges in 20 cases (40 %) and serum IGFBP-3 levels rose in
20 cases (40 %) but reached normal reference ranges in 11
cases (22 %). Similar results were obtained by Cesur et al,
2009 [16] who confirmed the fact that Zn supplementation
affects serum IGF-1 and IGFBP-3 levels in children with
Zn deficiency but due to the fact that Zn supplementation
was given for only two months, the increases in serum
IGF-1 and IGFBP-3 levels were still lower than the normal
range in most of their children; therefore, they suggested
that Zn supplementation may be necessary for longer
periods.
Conclusions
In conclusion, serum IGF-1 and IGFBP-3 levels were found
to be low in short children with Zn deficiency, and
increased after Zn supplementation for 3 months but their
levels were still lower than the normal reference ranges in
most children; therefore, Zn supplementation may be ne-
cessary for longer periods. In addition, GV did not differ
between Zn-deficient and healthy children with a better
GV observed in GH-deficient children. Further studies on
larger population scales and for longer periods are
warranted to explore the mechanism by which Zn defi-
ciency affects GH- IGF axis and to assess the effect of Zn
supplementation on it.
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